NKI

academic TIL programs at cancer institutes.

Country: Netherlands

EMA ATMP

Coverage

	CN	EU	US
therapeutics-platforms	✓	✓	✓

Regulatorsfdaemanmpa

Verifiable facts

Fact	Value	Source
Affiliation	The Netherlands Cancer Institute (NKI) is a comprehensive cancer center connected to the Antoni van Leeuwenhoek (AVL) hospital and is a member of EU-LIFE, Cancer Core Europe, and the Oncode Institute.	emerald-mdphd.eu · eu-life.eu · pragmatil.eu
Research focus	Cancer immunotherapy, with specific emphasis on tumor-infiltrating lymphocytes (TIL) therapy, breast cancer immunology, and cell-based screens.	emerald-mdphd.eu · eu-life.eu · nki.nl
Facility	Biotherapeutics Unit (BTU), which features four class A/B GMP-compliant cleanrooms for the production of T-cell products.	nki.nl
Grant	Includes funding from the Dutch Cancer Society (KWF), the European Union’s Horizon 2020 program (grant No 101034290), and other national/international project grants.	emerald-mdphd.eu · eu-life.eu · pragmatil.eu · nki.nl
Principal staff	John Haanen (Group leader, Cancer Immunotherapy), Cynthia Nijenhuis (Head, Biotherapeutics Unit), and Marleen Kok (Group leader, Breast Cancer Immunology & Immunotherapy).	nki.nl
Headcount	Over 750 scientists and scientific support staff members.	eu-life.eu
Publications	Researchers are highly cited, with key publications in journals including Nature and Cell.	nki.nl

Independent sources: emerald-mdphd.eu · eu-life.eu · nki.nl · pragmatil.eu

Technologies

Name	Cluster	Risk
TIL therapy (tumor-infiltrating lymphocytes)	therapeutics-platforms	Medium	→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.